Overview
- BioNTech, which unveiled the restructuring Tuesday, will wind down production in Marburg and Idar‑Oberstein in Germany, at former CureVac locations including Tübingen, and in Singapore by the end of 2027.
- The company will stop making COVID‑19 shots in Germany, with the last batches produced this year, and Pfizer will handle all manufacturing in Europe and the United States.
- Management targets about €500 million in yearly savings from 2029 to fund oncology research and launches, after first‑quarter revenue fell to €118.1 million and the net loss widened to €531.9 million.
- Works councils and the IG BCE union vowed to fight the closures, and CureVac founder Ingmar Hoerr accused BioNTech of misleading stakeholders over the takeover, a claim reported by media and not proven.
- In the most immediate fallout, CureVac staff in Tübingen and Wiesbaden were offered end‑of‑year severance deals, with local representatives saying about 750 people face losing their jobs.